Why did COLINZ.BO stock spike pre-market?

The spike was driven by concentrated buying and a volume surge in a low‑liquidity small-cap. There was no public earnings release; flows into healthcare micro-caps and short-covering likely caused the move.

What valuation metrics matter for COLINZ.BO stock?

Key metrics: **PE 30.16**, price-to-book **1.18**, cash per share **INR 29.46**, and debt-to-equity **0.07**. These show modest valuation, strong cash buffer, and low leverage.

What is Meyka AI's forecast for COLINZ.BO stock?

Meyka AI's forecast model projects a yearly price of **INR 54.50**, implying **-3.25%** from the current **INR 55.50**. Forecasts are model-based projections and not guarantees.

How should traders manage COLINZ.BO stock risk?

Use tight stops due to low average volume (**1,731**) and high intraday volatility. Consider entries on pullbacks to **INR 50.00–52.00** and size positions conservatively.

IN Stocks

COLINZ.BO up 20% pre-market: Colinz Laboratories Ltd (BSE) 28 Jan 2026 momentum

ByDanny Kontos January 28, 2026

COLINZ.BO stock opened the pre-market session sharply higher after a one-day jump of 20.00%, lifting Colinz Laboratories Limited to INR 55.50 on the BSE. The move follows an opening print of INR 50.00 and a previous close of INR 46.25, with intraday range from INR 49.75 to INR 55.50. Volume is elevated at 19,040 shares versus an average of 1,731, signalling concentrated buying. Traders should note this is a short-term momentum event inside a wider fiscal and technical context for the healthcare stock.